Affiliated with a Castle Connolly Top Hospital
Who is Dr. Colevas, Medical Oncologist in Stanford, CA?
Dr. Alexander Colevas, MD is a Medical Oncologist, who primarily practices in Stanford, CA with 1 additional practice location. He is board certified by the American Board of Internal Medicine. Dr. Colevas completed his residency at Johns Hopkins School of Medicine. Dr. Colevas is fluent in English, and is currently seeing new patients. Dr. Colevas’s practice accepts Kaiser Permanente, Medicaid, Medicare, UnitedHealthcare and other major insurance plans. To book an appointment or to confirm insurance options, please call Dr. Colevas’s office at (650) 498-6000.
What are Areas of Expertise for Dr. Colevas?
Dr. Alexander Colevas, MD is a highly-rated, board-certified Medical Oncologist known for expertly diagnosing, treating, and managing a wide array of related conditions or procedures. Utilizing the latest medical advancements and evidence-based practices, Dr. Colevas empowers patients to confidently navigate their health journey, specializing in Head & Neck Cancer, or comprehensive wellness support. Serving the Stanford/CA community, Dr. Colevas is dedicated to enhancing lives through expert, patient-centered care.
Where did Dr. Colevas go to medical school and complete their residency?
Fellowship: Dana Farber Cancer Institute
Residency: Johns Hopkins School of Medicine
Is Dr. Colevas board certified in Medical Oncologist?
Yes, Dr. Alexander Colevas, MD is board certified by the American Board of Internal Medicine since 1995
What languages does Dr. Colevas speak?
Dr. Colevas and their clinical team can communicate with patients in the following languages:
English
What conditions does Dr. Colevas treat?
As a Medical Oncologist, Dr. Colevas diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. Colevas. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly.
Also known as:
- Throat Cancer
- Oral Cancer
- Nasopharyngeal Cancer
- Malignant Neoplasm of Nasopharynx
- Pharyngeal Cancer
- Oropharyngeal Cancer
- Malignant Neoplasm of Oropharynx
- Tonsil Cancer
- Malignant Neoplasm of Tonsil
- Laryngeal Cancer
- Voice Box Cancer
- Malignant Laryngeal Tumor
ICD-10 Codes:
- C119: Malignant neoplasm of nasopharynx, unspecified
- C109: Malignant neoplasm of oropharynx, unspecified
- C099: Malignant neoplasm of tonsil, unspecified
- C329: Malignant neoplasm of larynx, unspecified
Also known as:
- Thyroid Cancer
- Thyroid Carcinoma
- Malignant Thyroid Nodule
- Thyroid Gland Cancer
ICD-10 Codes:
- C73: Malignant neoplasm of thyroid gland
Also known as:
- Oral Cancer
- Mouth Cancer
- Tongue Cancer
- Oral Cavity Cancer
- Tongue Carcinoma
- Malignant Neoplasm of Tongue
- Mouth Malignancy
- Oral Carcinoma
ICD-10 Codes:
- C01: Malignant neoplasm of base of tongue
- C029: Malignant neoplasm of tongue, unspecified
- C069: Malignant neoplasm of mouth, unspecified
Also known as:
- Salivary Gland Cancer
- Parotid Gland Cancer
- Salivary Gland Tumor
- Salivary Gland Carcinoma
- Major Salivary Gland Cancer
ICD-10 Codes:
- C07: Malignant neoplasm of parotid gland
- C089: Malignant neoplasm of major salivary gland, unspecified
Also known as:
- Squamous Cell Skin Cancer of the Scalp or Neck
- Skin Cancer
- Squamous Cell Skin Cancer of the Face
- Skin Cancer Treatment (PDQ®)
- Squamous Cell Carcinoma of Scalp
- Squamous Cell Carcinoma of Neck
- Scalp SCC
- Neck SCC
- Squamous Cell Carcinoma
- SCC
- Malignant Skin Tumor
- Squamous Cell Carcinoma of Face
- Facial SCC
- Cutaneous Squamous Cell Carcinoma of Face
- Face Skin Malignancy
ICD-10 Codes:
- C4442: Squamous cell carcinoma of skin of scalp and neck
- C4492: Squamous cell carcinoma of skin, unspecified
- C44329: Squamous cell carcinoma of skin of other parts of face
Also known as:
- Head and Neck Cancer
- Nasal Cancer
- Head Cancer
- Neck Cancer
- Facial Cancer
- Malignant Head and Neck Tumor
- Nasal Cavity Cancer
- Nose Cancer
- Malignant Nasal Tumor
ICD-10 Codes:
- C760: Malignant neoplasm of head, face and neck
- C300: Malignant neoplasm of nasal cavity
Also known as:
- Cancer Chemotherapy
- Cancer Immunotherapy
- Chemo treatment
- Oncology chemotherapy
- Cancer drug therapy
- Oncology immunotherapy
- Immune therapy for cancer
ICD-10 Codes:
- Z5111: Encounter for antineoplastic chemotherapy
- Z5112: Encounter for antineoplastic immunotherapy
Also known as:
- Primary Cancer (Unspecified Site)
- Secondary Cancer (Other Specified Sites)
- Cancer
- Malignant tumor
- Neoplasm
- Cancer of unknown primary
- Metastatic cancer
- Cancer spread to other organs
- Cancer metastases
ICD-10 Codes:
- C801: Malignant (primary) neoplasm, unspecified
- C7989: Secondary malignant neoplasm of other specified sites
Also known as:
- Oropharyngeal Dysphagia
- Swallowing Disorder
- Difficulty Swallowing in Throat
- Trouble Starting to Swallow
- Throat Swallowing Problems
ICD-10 Codes:
- R1312: Dysphagia, oropharyngeal phase
Which procedures does Dr. Colevas perform as a Medical Oncologist?
As a Medical Oncologist, procedures performed by a Dr. Alexander Colevas may include:
- 3D Conformal Radiotherapy
- Adaptive Radiation Therapy (ART)
- Adrenalectomy
- Blood Thinning Therapy / Anticoagulation
- Blood Transfusion Consultation
- Blood Transfusion Follow Up
- Bone Excision
- Bone Grafting
For detailed information, please contact Dr. Colevas' office.
Does Dr. Colevas accept my insurance?
Dr. Colevas accepts most major insurance plans. Important: Please call our office at (650) 498-6000 before your appointment to verify that your specific plan and network are accepted.
What insurance plans does Dr. Colevas accept in Stanford, CA?
Dr. Colevas in Stanford, CA accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.
Top Insurances
Alignment Health Plan
All Other Third Party
Blue Shield of California
CVS Health (formerly Aetna)
Express Scripts
Medicaid
Medicare
OptumRx
Santa Clara Family Health Plan
UnitedHealthcare
View All Insurances
Where is Dr. Colevas' office located?
Recognitions
Publications
Head and Neck Cancers, Version 2.2013 Featured Updates to the NCCN Guidelines
JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORK, 2013
Stereotactic radiosurgery for retreatment of gross perineural invasion
American jourl of clinical oncology, 2013
Biased View of the Role of Site-Specific Therapy in Carcinoma of Unknown Primary.
Jourl of clinical oncology : official jourl of the American Society of
Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3
INVESTIGATIOL NEW DRUGS, 2012
Tumor Volume-Adapted Dosing in Stereotactic Ablative Radiotherapy of Lung Tumors
INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012
A phase I dose-escalation study of aflibercept administered in combition with pemetrexed
BRITISH JOURL OF CANCER, 2012
Validation that Metabolic Tumor Volume Predicts Outcome in Head-and-Neck Cancer
INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012
Phase I trial of the combition of flavopiridol and imatinib mesylate in patients with Bcr-Abl
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012
Effect of stimulation of tural killer cells with an anti-CD137 mAb on the efficacy of trastuzumab
Kohrt, H. E., Houot, R., Weiskopf, K., Goldstein, M., Lund, P., Scheer
Intensity-Modulated Radiotherapy for Tumors of the sal Cavity and Parasal Sinuses
Wiegner, E. A., Daly, M. E., Murphy, J. D., Abelson, J., Chapman, C. H, 2012
Maintence Bevacizumab is Associated With Increased Hemoglobin in Patients With Advanced
CANCER INVESTIGATION, 2012
Mucosal Melanoma of the Head and Neck
JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORK, 2012
Stimulation of tural killer cells with a CD137
JOURL OF CLINICAL INVESTIGATION, 2012
Addition of bevacizumab to st
LANCET ONCOLOGY, 2012
The use of epidermal growth factor receptor monoclol antibodies
Chemotherapy research and practice, 2012
Head and Neck Cancers
JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORK, 2011
Controversies in the Locoregiol Magement of Head and Neck Cancer
JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORK, 2011
INTENSITY-MODULATED RADIOTHERAPY FOR LOCALLY ADVANCED CANCERS OF THE LARYNX AND HYPOPHARYNX
HEAD AND NECK-JOURL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND N, 2011
A Phase II First-Line Study of Gemcitabine, Carboplatin
JOURL OF THORACIC ONCOLOGY, 2010
HIGHER INCIDENCE OF HEAD AND NECK CANCERS AMONG VIETMESE AMERICAN MEN IN CALIFORNIA
HEAD AND NECK-JOURL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND N, 2010
MOLECULAR AND CLINICAL RESPONSES IN A PILOT STUDY OF GEFITINIB WITH PACLITAXEL AND RADIATION IN
INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010
LONG-TERM OUTCOMES AND TOXICITY OF CONCURRENT PACLITAXEL AND RADIOTHERAPY FOR LOCALLY ADVANCED HEAD
INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009
Does Pre-treatment Metabolic Tumor Growth Rate (MTGR) Predict Progression in Lung Cancer?
Eastham, D. V., Chapman, C. H., Rao, A. K., rasimhan, B., Quon, A., Va, 2009
A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone
BRITISH JOURL OF HAEMATOLOGY, 2008
Head and neck cancers.
Jourl of the tiol Comprehensive Cancer Network, 2008
Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck
INVESTIGATIOL NEW DRUGS, 2008
Patient-reported outcomes and the evolution of adverse event reporting in oncology
JOURL OF CLINICAL ONCOLOGY, 2007
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer
NEW ENGLAND JOURL OF MEDICINE, 2007
A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors
INVESTIGATIOL NEW DRUGS, 2007
Phase I and correlative biology study of cilengitide in patients with recurrent malignt glioma
JOURL OF CLINICAL ONCOLOGY, 2007
A phase II study of ixabepilone (BMS-247550) in metastatic rel-cell carcinoma
CANCER BIOLOGY & THERAPY, 2007
Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea
EUROPEAN JOURL OF CANCER, 2007
Adverse event reporting in publications compared with sponsor database for cancer clinical trials
JOURL OF CLINICAL ONCOLOGY, 2006
Chemotherapy options for patients with met
JOURL OF CLINICAL ONCOLOGY, 2006
Phase II evaluations of cilengitide in asymptomatic patients with
CLINICAL GENITOURIRY CANCER, 2006
Ixabepilone (epothilone B alogue BMS
JOURL OF CLINICAL ONCOLOGY, 2005
Phase I trial and pharmacokinetics of escalating doses of paclitaxel
CANCER, 2005
Multi-institutiol randomized phase II trial of the epothilone B alog ixabepilone
JOURL OF CLINICAL ONCOLOGY, 2005
Phase II trial of flavopiridol, a cyclin dependent kise inhibitor
INVESTIGATIOL NEW DRUGS, 2004
CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer
SEMIRS IN RADIATION ONCOLOGY, 2003
Development of investigatiol radiation modifiers
JOURL OF THE TIOL CANCER INSTITUTE, 2003
Phase I/II trial of outpatient docetaxel
AMERICAN JOURL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2002
Hypothyroidism incidence after multimodality treatment for stage III
INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001
Clinical trials referral resource: Current clinical trials of epothilone B alog (BMS-247550)
ONCOLOGY-NEW YORK, 2001
Multicenter phase I-II trial of docetaxel, cisplatin
JOURL OF CLINICAL ONCOLOGY, 2001
The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head
SEMIRS IN ONCOLOGY, 2000
A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous
ANLS OF ONCOLOGY, 2000
Phase II trial of docetaxel, cisplatin
JOURL OF CLINICAL ONCOLOGY, 1999
Intramucosal spread of malignt melanoma of the oral cavity
OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 1998
Docetaxel in head and neck cancer - A review
AMERICAN JOURL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1998
Induction chemotherapy with docetaxel, cisplatin
JOURL OF CLINICAL ONCOLOGY, 1998
Long-Term Outcomes of Surgery Followed by Radiation Therapy for Minor Salivary Gland Carcinomas
LARYNGOSCOPE, 2013
Head and Neck Cancers, Version 2.2013 Featured Updates to the NCCN Guidelines
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2013
Stereotactic radiosurgery for retreatment of gross perineural invasion
American journal of clinical oncology, 2013
Impact of positron emission tomography
CANCER, 2013
Biased View of the Role of Site-Specific Therapy in Carcinoma of Unknown Primary.
Journal of clinical oncology : official journal of the American Societ
Population-based evaluation of incidence trends in oropharyngeal cancer focusing on socioeconomic
Head & neck
Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013
Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3
INVESTIGATIONAL NEW DRUGS, 2012
A Phase 2 Trial of Flavopiridol
GYNECOLOGIC ONCOLOGY, 2012
Tumor Volume-Adapted Dosing in Stereotactic Ablative Radiotherapy of Lung Tumors
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012
A phase I dose-escalation study of aflibercept administered in combination with pemetrexed
BRITISH JOURNAL OF CANCER, 2012
Validation that Metabolic Tumor Volume Predicts Outcome in Head-and-Neck Cancer
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012
A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma
MELANOMA RESEARCH, 2012
Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012
Effect of stimulation of natural killer cells with an anti-CD137 mAb on the efficacy of trastuzumab
Kohrt, H. E., Houot, R., Weiskopf, K., Goldstein, M., Lund, P., Scheer
Intensity-Modulated Radiotherapy for Tumors of the Nasal Cavity and Paranasal Sinuses
Wiegner, E. A., Daly, M. E., Murphy, J. D., Abelson, J., Chapman, C. H, 2012
A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012
Maintenance Bevacizumab is Associated With Increased Hemoglobin in Patients With Advanced
CANCER INVESTIGATION, 2012
Mucosal Melanoma of the Head and Neck
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2012
Stimulation of natural killer cells with a CD137
JOURNAL OF CLINICAL INVESTIGATION, 2012
Addition of bevacizumab to st
LANCET ONCOLOGY, 2012
The use of epidermal growth factor receptor monoclonal antibodies
Chemotherapy research and practice, 2012
Head and Neck Cancers
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2011
Controversies in the Locoregional Management of Head and Neck Cancer
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2011
INTENSITY-MODULATED RADIOTHERAPY FOR LOCALLY ADVANCED CANCERS OF THE LARYNX AND HYPOPHARYNX
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND, 2011
A Phase II First-Line Study of Gemcitabine, Carboplatin
JOURNAL OF THORACIC ONCOLOGY, 2010
HIGHER INCIDENCE OF HEAD AND NECK CANCERS AMONG VIETNAMESE AMERICAN MEN IN CALIFORNIA
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND, 2010
MOLECULAR AND CLINICAL RESPONSES IN A PILOT STUDY OF GEFITINIB WITH PACLITAXEL AND RADIATION IN
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010
Excellent early local control with tumor volume adapted dosing of stereotactic body radiation
Chang, C. N., Zhou, L. Y., MacFarlane, G., Tran, P., Rao, A., Chapman,, 2009
LONG-TERM OUTCOMES AND TOXICITY OF CONCURRENT PACLITAXEL AND RADIOTHERAPY FOR LOCALLY ADVANCED HEAD
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009
Does Pre-treatment Metabolic Tumor Growth Rate (MTGR) Predict Progression in Lung Cancer?
Eastham, D. V., Chapman, C. H., Rao, A. K., Narasimhan, B., Quon, A., , 2009
A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone
BRITISH JOURNAL OF HAEMATOLOGY, 2008
Head and neck cancers.
Journal of the National Comprehensive Cancer Network, 2008
Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck
INVESTIGATIONAL NEW DRUGS, 2008
Patient-reported outcomes and the evolution of adverse event reporting in oncology
JOURNAL OF CLINICAL ONCOLOGY, 2007
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer
NEW ENGLAND JOURNAL OF MEDICINE, 2007
A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors
INVESTIGATIONAL NEW DRUGS, 2007
Sequential flavopiridol, cytosine arabinoside
CLINICAL CANCER RESEARCH, 2007
Inhibition of poly (ADP
CLINICAL CANCER RESEARCH, 2007
Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma
JOURNAL OF CLINICAL ONCOLOGY, 2007
A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma
CANCER BIOLOGY & THERAPY, 2007
Flavopiridol administered using a pharmacologically derived schedule is
BLOOD, 2007
Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea
EUROPEAN JOURNAL OF CANCER, 2007
Adverse event reporting in publications compared with sponsor database for cancer clinical trials
JOURNAL OF CLINICAL ONCOLOGY, 2006
Chemotherapy options for patients with met
JOURNAL OF CLINICAL ONCOLOGY, 2006
Phase II evaluations of cilengitide in asymptomatic patients with
CLINICAL GENITOURINARY CANCER, 2006
In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea
CLINICAL CANCER RESEARCH, 2005
Phase I and pharmacokinetic study of flavopiridol followed by 1-beta
CLINICAL CANCER RESEARCH, 2005
Ixabepilone (epothilone B analogue BMS
JOURNAL OF CLINICAL ONCOLOGY, 2005
Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent
CANCER, 2005
Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone
JOURNAL OF CLINICAL ONCOLOGY, 2005
Current clinical trials of cilengitide
ONCOLOGY-NEW YORK, 2004
Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor
INVESTIGATIONAL NEW DRUGS, 2004
HER2 expression in salivary gland carcinomas: Dependence on histological subtype
CLINICAL CANCER RESEARCH, 2004
Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study
ORAL ONCOLOGY, 2003
CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer
SEMINARS IN RADIATION ONCOLOGY, 2003
Development of investigational radiation modifiers
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003
Docetaxel, cisplatin
CANCER, 2003
Organ preservation-induction chemotherapy.
Cancer treatment and research, 2003
Timed sequential therapy of acute leukemia with flavopiridol
CLINICAL CANCER RESEARCH, 2003
A Phase I/II trial of concurrent docetaxel and radiation
CANCER, 2002
Phase I/II trial of outpatient docetaxel
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2002
Hypothyroidism incidence after multimodality treatment for stage III
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001
Clinical trials referral resource: Current clinical trials of epothilone B analog (BMS-247550)
ONCOLOGY-NEW YORK, 2001
A Phase II study of combined oral uracil
Colevas, A. D., Amrein, P. C., Gomolin, H., Barton, J. J., Read, R. R., 2001
Multicenter phase I-II trial of docetaxel, cisplatin
JOURNAL OF CLINICAL ONCOLOGY, 2001
NCCN Practice Guidelines for head and neck cancers
ONCOLOGY-NEW YORK, 2000
The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head
SEMINARS IN ONCOLOGY, 2000
A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous
ANNALS OF ONCOLOGY, 2000
Phase II trial of docetaxel, cisplatin
JOURNAL OF CLINICAL ONCOLOGY, 1999
Re: Sialadenosis: a presenting sign in Bulemia (Head and Neck 20: 758-762, 1998)
Head & neck, 1999
An initial experience using concurrent paclitaxel and radiation
Tishler, R. B., Busse, P. M., Norris, C. M., Rossi, R., Poulin, M., Th, 1999
Intramucosal spread of malignant melanoma of the oral cavity
OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 1998
Docetaxel in head and neck cancer - A review
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1998
Induction chemotherapy with docetaxel, cisplatin
JOURNAL OF CLINICAL ONCOLOGY, 1998
The Prognostic Value of Thymidylate Synthase
The oncologist, 1998
Future directions in the treatment of squamous cell carcinoma of the head and neck
Oncology (Williston Park, N.Y.), 1997
What is Dr. Colevas's NPI number?An National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.
Dr. Colevas's National Provider Identifier (NPI) number is 1588726558.
What common questions do patients ask about Dr. Colevas?
Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Colevas
What is Dr. Alexander Colevas's specialty?
Dr. Colevas is a Medical Oncologist near Stanford, CA. An internist specializing in the diagnosis and treatment of various cancers and both benign and malignant tumors. This specialist determines and administers therapy for malignancies and collaborates with surgeons and radiation oncologists on additional cancer treatment options. Contact Dr. Colevas to book an appointment today.
Is this Dr. Alexander Colevas affiliated with a ranked Castle Connolly Top Hospital?
Yes, Dr. Colevas is affiliated with Stanford Health Care - Stanford Hospital which is a Castle Connolly Top Hospital. Castle Connolly Top Hospitals are healthcare institutions recognized for their excellence in specific medical procedures and overall patient care. They are identified through a rigorous peer nomination process, evaluating factors like patient outcomes, quality of care, and expertise. The list recognizes hospitals that excel in 20 or more specific medical procedures, representing the top 25% nationwide. Castle Connolly Top Hospitals
Where can I learn more about Medical Oncologist?
Explore Medical Oncologist with insights from trusted medical experts on EverydayHealth.com, where you'll find the most relevant content and helpful condition guides for up-to date information about symptoms, causes, diagnosis, treatment and more. See all our health guides to find trusted information on medical conditions from our experts at Everyday Health.
Is Alexander Colevas accepting new patients in Stanford, CA?
Yes, Dr. Alexander Colevas is accepting new patients at this time.
Does Dr. Alexander Colevas offer online booking?
Please contact Dr. Colevas's office at (650) 498-6000 for information about online booking, telehealth, or to schedule an appointment.
How can I make an appointment with Alexander Colevas?
Please contact Dr. Colevas's office at (650) 498-6000 for information regarding telehealth appointment availability or for scheduling assistance.
Which board certifications does Dr. Alexander Colevas have?
Dr. Alexander Colevas is certified by the American Board of Internal Medicine.
Other Medical Oncologist Near Stanford, CA
Hematologist
Accepting patientsMedical Oncologist
Accepting patientsMedical Oncologist
Accepting patients